Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Robert Burger MD
To estimate the proportion of patients who survive progression-free for atleast 6 months and the proportion of patients who have objective tumorresponse (complete or partial) in patients with persistent or recurrentepithelial ovarian, fallopian tube, or primary peritoneal carcinoma, treatedwith dalantercept.
To determine the frequency and severity of adverse events associated withtreatment with dalantercept as assessed by the Active Version of theNational Cancer Institute (NCI) Common Terminology Criteria forAdverse Events (CTCAE).
Patients who survive progression-free for at least 6 months and patients who have objective tumor response (complete or partial) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, treatedwith dalantercept.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.